Spots Global Cancer Trial Database for IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: IBI310 in Combination With Sintilimab in Patients With Advanced Biliary Tract Cancer
Official Title: A Single Arm,Multi-center,Phase Ib/II Clinical Study Evaluating IBI310 Combined With Sintilimab in Patients With Advanced Biliary Tract Cance(BTC)
Study ID: NCT05653180
Conditions
Study Description
Brief Summary: This research study is designed to establish whether the combination of IBI310 \& Sintilimab has efficacy in patients with advanced BTC
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Hunan cancer Hospital, Changsha, Hunan, China
Contact Details
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
